Apr 26, 2018

Big pharma's monster early haul in Q1

Bristol-Myers Squibb raked in $1.5 billion of profit in the first quarter of 2018. Photo: John Greim/LightRocket via Getty Images

Seven of the world's largest pharmaceutical companies — AbbVie, Amgen, Novartis, GlaxoSmithKline, Bristol-Myers Squibb, Eli Lilly and Biogen — cumulatively collected $12.1 billion of profit in the first three months of 2018. That's up 29% from the same time last year.

The bottom line: Drug makers have not been shy about raising list prices on previously approved medications, despite President Trump's rhetoric about going after the industry.

Some highlights from those companies thus far:

  • Amgen CEO Bob Bradway said on an earnings call that his company will "work with Congress and the administration to advocate for policies that improve the affordability and access to important new medicines." Lobbying reports show Amgen has attempted to influence bills that would allow prescription drugs to be imported from other countries.
  • The Trump administration has made it clear it is focused on a handful of drug pricing issues, like Medicare Part B and the federal discount program for hospitals known as 340B. "I don't think they're new," Novartis CEO Vas Narasimhan said.
  • AbbVie's Humira treatment remains the lifeblood of the company, representing about 60% of its revenue.
  • Earnings still to come: Pfizer, Merck, Gilead Sciences, Novo Nordisk and Celgene report next week.

Go deeper

Scoop: Inside the Trump campaign's big hedge on Facebook

Illustration: Eniola Odetunde/Axios

The Trump campaign has invested most of its advertising budget to date on Facebook, testing thousands of versions of ads per day to maximize its spending.

But behind the scenes, a source familiar with the campaign tells Axios, the thinking has shifted: "As everyone can see, we still have strong spending on Facebook, but the percentage of our total media budget [on Facebook] is shrinking."

Trump's revenge tour has the House in its sights

Illustration: Aïda Amer/Axios. Photo: Saul Loeb/Getty Contributor

In the lead-up to the 2018 midterm elections — buoyed by Republican control of both chambers — President Trump viewed campaigning for the House as a lower-tier priority and instead poured his energy into rallying for the Senate.

But after the GOP reckoning in 2018, and experiencing firsthand how damaging a Democratic-led House has been to him, Trump is now personally invested in helping Republicans regain the majority in November, several people familiar with his thinking tell Axios.

Pelosi warns U.S. allies against working with China's Huawei

Nancy Pelosi, Feb. 16. Photo: Sven Hoppe/picture alliance via Getty Images

House Speaker Nancy Pelosi on Sunday cautioned U.S. allies against allowing Chinese telecommunications giant Huawei to develop their 5G networks, arguing at the Munich Security Conference that doing so is akin to “choosing autocracy over democracy," CNBC reports.

Why it matters: Pelosi's hawkish stance marks a rare area of agreement with the Trump administration, which believes Huawei is a national security threat because the Chinese government may be capable of accessing its equipment for espionage.

Go deeperArrow4 hours ago - World